SCYNEXIS Stock

SCYNEXIS FCF Growth

The Year-over-Year Free Cash Flow Growth of SCYNEXIS (SCYX) as of Aug 7, 2026 is -139.91 %. In the previous year, Year-over-Year Free Cash Flow Growth was 175.30 % — a change of -179.81% (lower).

FCF Growth

-139.91 %

YoY

-179.81%

Last updated:

Year-over-Year Free Cash Flow Growth of SCYNEXIS is 2026 -139.91 % . Year-over-Year Free Cash Flow Growth of SCYNEXIS was 2025 175.30 % . It decreases by -179.81% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Year-over-Year Free Cash Flow Growth of SCYNEXIS is -139.91 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Growth — SCYNEXIS

All Key Metrics — SCYNEXIS